Comparison of dimethyl fumarate and interferon outcomes in an MS cohort

Area of Science:

• Neuroimmunology
• Clinical Neurology
• Pharmacology

Background:

• Relapsing-remitting Multiple Sclerosis (MS) poses significant challenges in disease management.
• Interferon beta-1a (IFNβ-1a) and dimethyl fumarate (DMF) are established treatments for MS.
• Comparing the efficacy of these disease-modifying therapies is crucial for optimizing patient outcomes.

Purpose of the Study:

• To evaluate and compare the effectiveness of dimethyl fumarate (DMF) versus subcutaneous interferon beta-1a (IFNβ-1a) in controlling disease activity in patients diagnosed with relapsing-remitting Multiple Sclerosis (MS).

Main Methods:

• A retrospective review of clinical and imaging data was conducted for patients with MS treated with either IFNβ-1a or DMF for a minimum of one year.
• Key outcome measures included the proportion of patients experiencing clinical relapses, the occurrence of new T2 or gadolinium-enhancing MRI lesions, and the achievement of no evidence of disease activity (NEDA) status at 15 months post-treatment initiation.

Main Results:

• The study included 316 patients (218 on DMF, 98 on IFNβ-1a).
• Patients treated with DMF exhibited a significantly lower proportion of clinical relapses (9.6% vs. 24.5%) and new MRI lesions (8.7% vs. 28.6%) compared to those on IFNβ-1a at 15 months.
• A substantially higher percentage of patients achieved NEDA status with DMF (79.9%) compared to IFNβ-1a (51.1%).

Conclusions:

• Dimethyl fumarate (DMF) is associated with significantly reduced clinical and radiological disease activity in patients with relapsing-remitting Multiple Sclerosis (MS) when compared to subcutaneous interferon beta-1a (IFNβ-1a).
• DMF treatment leads to a greater likelihood of achieving no evidence of disease activity (NEDA).